AZENT

orange__line

A Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of Osimertinib (AZD9291) in First-line Patients With EGFR Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer and Concomitant EGFR T790M Mutation at Time of Diagnosis.

The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as defined by RECIST 1.1 criteria.

Safety and efficacy will also be measured.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
AZENT NSCLC Safety and efficacy study of AZD9291 in treatment-naïve patients with EGFR mutant NSCLC and concomitant EGFR T790M pretreatment II 21 7 Spain Actively enrolling patients

Botón CONTACT US